Skip to main content
SpringerLink
Log in

Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

In patients receiving fibrinolytic therapy for ST-elevation myocardial infarction (STEMI), adjunct treatment with enoxaparin has been shown to provide superior net clinical benefit compared with unfractionated heparin (UFH) in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment — Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 study. The objective of this study was to compare the cost effectiveness of enoxaparin and UFH strategies.

Methods

A cost-utility analysis was conducted using a two-stage model: (1) A 30-day decision tree analytical model for the acute treatment phase, and (2) a lifetime Markov model (from 30 days post-STEMI until death) populated using patient survival data.

Results

Assuming treatment continuation for 7 days, the mean day 1–30 incremental cost associated with enoxaparin was £49 per patient, and mean lifetime incremental cost was £592 per patient (£91,091 vs. £90,499, respectively). Given an additional 0.048 life years gained per patient with enoxaparin, the cost per life year saved was £12,353, and given an additional 0.038 quality-adjusted life years (QALY) per patient with enoxaparin, the cost per QALY was £15,413. In an alternative scenario, reflecting contemporary practice assuming early treatment discontinuation at 48 hours, for example following urgent revascularization, the incremental cost per QALY was £13,556.

Conclusion

The use of an enoxaparin versus UFH strategy in patients receiving fibrinolytic therapy for STEMI, whether continued for 7 days or discontinued early, for example following urgent revascularization, is cost effective at a £20,000 willingness-to-pay threshold.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–2945.

    Article  PubMed  Google Scholar 

  2. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol. 2005;95:100–101.

    Article  PubMed  Google Scholar 

  3. Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118:268–276.

    Article  PubMed  Google Scholar 

  4. Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530–1538.

    Article  PubMed  Google Scholar 

  5. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation. 2008;117:296–329.

    Article  PubMed  Google Scholar 

  6. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682.

    Article  Google Scholar 

  7. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716–722.

    Article  Google Scholar 

  8. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855–1863.

    Article  CAS  PubMed  Google Scholar 

  9. Antman EM. The search for replacements for unfractionated heparin. Circulation. 2001;103:2310–2314.

    CAS  PubMed  Google Scholar 

  10. Menown IBA. New anticoagulant strategies In ST-elevation myocardial infarction treated with fibrinolytic therapy. Br J Cardiol. 2008:15:87–94

    Google Scholar 

  11. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488.

    Article  CAS  PubMed  Google Scholar 

  12. Montalescot G, Philippe F, Ankri A, et al. for the French Investigators of the ESSENCE trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation. 1998;98:294–299.

    CAS  PubMed  Google Scholar 

  13. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98:287–289.

    CAS  PubMed  Google Scholar 

  14. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IBA, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction. A meta-analysis of the randomized trials. Circulation. 2005;112:3855–3867.

    Article  CAS  PubMed  Google Scholar 

  15. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077–2086.

    Article  CAS  PubMed  Google Scholar 

  16. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782.

    Article  PubMed  Google Scholar 

  17. Carruthers KF, Dabbous OH, Flather MD, et al. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart. 2005;91:290–298.

    Article  CAS  PubMed  Google Scholar 

  18. Robinson M, Palmer S, Sculpher M, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess. 2005;9:1–158.

    CAS  PubMed  Google Scholar 

  19. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003;21(suppl. 1):43–50.

    Article  PubMed  Google Scholar 

  20. HM Treasury. Green Book: Appraisal and evaluation in central government. 2003. Available at: www.hm-treasury.gov.uk/d/green_book_complete.pdf. Accessed June 1, 2008.

  21. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457–1466.

    Article  PubMed  Google Scholar 

  22. British National Formulary website. BNF 55. Available at: www.bnf.org.uk. Accessed May 1, 2008.

  23. Newcastle Upon Tyne NHS Trust. Newcastle Upon Tyne Hospital NHS Trust Provider Tariff 2005/6 — Haematology. Newcastle Upon Tyne: NHS; 2006.

    Google Scholar 

  24. Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord. 2001;1:2.

    Article  CAS  PubMed  Google Scholar 

  25. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–749.

    Article  PubMed  Google Scholar 

  26. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21:191–200.

    Article  PubMed  Google Scholar 

  27. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321–330.

    Article  CAS  PubMed  Google Scholar 

  28. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Available at: www.york.ac.uk/inst/che/pdf/DP172.pdf 1999. Accessed June 1, 2008.

  29. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and inhospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358–363.

    Article  PubMed  Google Scholar 

  30. Detournay B, Huet X, Fagnani F, Montalescot G. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial. Pharmacoeconomics. 2000;18:83–89.

    Article  CAS  PubMed  Google Scholar 

  31. Marcoff L, Zhang Z, Zhang W, et al. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study. J Am Coll Cardiol. 2009;54:1271–1279.

    Article  PubMed  Google Scholar 

  32. Welsh RC, Sauriol L, Zhang Z, Kolm P, Weintraub WS, Theroux P. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment — Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial. Can J Cardiol. 2009;25:e399–405.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Craigavon Cardiac Centre, Craigavon, BT63 5QQ, Northern Ireland, UK

    Ian Menown, Gilles Montalescot & Nikhal Pal

  2. Abacus International, Bicester, UK

    Carrie Fidler, Michelle Orme & Samantha Gillard

Authors
  1. Ian Menown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilles Montalescot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikhal Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carrie Fidler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michelle Orme
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samantha Gillard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Menown.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Menown, I., Montalescot, G., Pal, N. et al. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice. Adv Therapy 27, 181–191 (2010). https://doi.org/10.1007/s12325-010-0013-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0013-x

Keywords

Search

Navigation